Piper Jaffray bullish on Nektar, more confident in Phase III study success
Following Nektar's updated data from the melanoma cohort at SITC, Piper Jaffray analyst Tyler Van Buren says it is clear that everyone has been "too myopic" by solely focusing on overall response rates. Despite this, the analyst says that it was "encouraging to see" it actually increase to 53% following independent central radiology, and compares well to nivo monotherapy. More importantly, a 24% CR rate is "impressive" at this stage, he contends. The analyst argues that the more durable responses appear to be translating to improved mPFS as it is not nearly reached with the study having about 8 months of median follow-up. Van Buren reiterates an Overweight rating and $125 price target on the shares as he is now incrementally more confident in Phase III study success.